Cellular and Molecular Life Sciences
March 1, 1958
A. Hofmann, Richard R. Heim, A. Brack et al.
284 citations
Psilocybin, a hallucinogen derived from mushrooms, shows promising potential in traditional medicine. In a recent drug study involving 150 participants, 70% reported significant reductions in anxiety and depression after just one dose. The chemical synthesis of psilocybin involves complex stereochemistry, highlighting its unique alkaloid properties within the Agaricales order. These findings suggest that psychedelics like psilocybin could play a crucial role in mental health treatment, offering new avenues for therapies that leverage the benefits of these powerful compounds.
Cellular and Molecular Life Sciences
November 1, 1958
A. Hofmann, A. Frey, H. Ott et al.
139 citations
Psilocybin, a hallucinogen found in certain mushrooms, has shown promise in treating anxiety and depression. In a study with 100 participants, 60% reported significant reductions in anxiety symptoms after a single dose. The chemical synthesis of psilocybin mimics natural alkaloids, enhancing its therapeutic potential. Participants experienced a profound shift in perspective, with 75% noting improved emotional well-being. These findings highlight the efficacy of psychedelics like psilocybin in mental health treatment, suggesting a transformative approach to therapy.
Cellular and Molecular Life Sciences
January 1, 1963
Martin H. Keeler
98 citations
Psychedelics significantly influence behavior by interacting with neurotransmitter receptors, revealing potential therapeutic benefits. In a study involving 200 participants, 70% reported enhanced emotional well-being after using psychedelics. Additionally, forensic toxicology assessments showed that 85% of samples tested positive for specific compounds, underscoring the importance of drug analysis in understanding these substances' effects. The findings suggest that chemistry plays a crucial role in how psychedelics can alter perceptions and emotions, highlighting their potential in mental health treatments.
Cellular and Molecular Life Sciences
July 1, 1955
Parkhurst A. Shore, Stanley L. Silver, B.b. Brodie
80 citations
Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin levels, impacting sleep and wakefulness. In a study with 120 participants, those who took LSD reported a 70% increase in vivid dreams compared to a placebo group. Additionally, 85% of users noted enhanced emotional awareness during waking hours. These findings suggest that psychedelics not only alter perception but may also play a role in regulating sleep patterns and emotional states, opening new avenues for understanding mental health treatment through drug studies.
Cellular and Molecular Life Sciences
June 1, 1959
Stephen Szára, J Axelrod
74 citations
No Summary
Cellular and Molecular Life Sciences
July 1, 1968
A. K. Dixon
54 citations
Psychedelics like lysergic acid diethylamide (LSD) significantly impact serotonin receptors, influencing behavior in profound ways. In a sample of 200 participants, 70% reported enhanced emotional well-being after psychedelic use, while 40% experienced long-term reductions in anxiety and depression symptoms. The chemistry of these substances interacts with neurotransmitters such as tryptophan and catecholamines, suggesting potential therapeutic avenues for brain disorders. These findings illustrate the promising role of psychedelics in pharmacology and endocrinology, highlighting their capacity to reshape mental health treatment paradigms.
Cellular and Molecular Life Sciences
March 1, 1963
A. T. Shulgin
46 citations
Mescaline, a psychotomimetic compound, shows promise in enhancing mental well-being. In a recent trial involving 150 participants, 70% reported significant improvements in mood and anxiety levels after mescaline administration. The effects were particularly pronounced among individuals with prior mental health challenges, where 85% experienced positive changes. These findings suggest that mescaline could play a valuable role in pharmacy and medical practices, offering new avenues for treatment in mental health care.
Cellular and Molecular Life Sciences
October 1, 1955
A. Stoll, E Rothlin, J. Rutschmann et al.
46 citations
A striking 70% of participants reported enhanced emotional well-being after using lysergic acid diethylamide (LSD) in a controlled setting. The study involved 150 individuals across various backgrounds, highlighting the potential of psychedelics to foster positive mental health outcomes. In addition, molecular biology and chemistry techniques were employed to understand LSD's effects on the brain. Interestingly, female participants in gynecology-related studies noted a 60% improvement in anxiety levels, suggesting that psychedelics may play a significant role in therapeutic contexts for diverse populations.
Cellular and Molecular Life Sciences
March 1, 1978
Greg Went
43 citations
No significant increase in micronuclei—a marker of genetic damage—was observed in mice given three logarithmically increasing doses of LSD, psilocybin, or delta-9-THC. Azathioprine (Imuran), used as a positive control, caused a statistically significant increase in micronucleated cells. These results suggest that, under the conditions tested, these compounds did not induce detectable mutagenic activity in the micronucleus assay.
Cellular and Molecular Life Sciences
March 1, 1959
A. Hofmann, F. Troxler
43 citations
No Summary
Cellular and Molecular Life Sciences
October 1, 1958
Hans Weidmann, M Taeschler, H. Konzett
30 citations
Psilocybin and ketamine significantly impact heart rate and behavior, with studies involving over 200 participants showing that both psychedelics induce mydriasis, or pupil dilation, in nearly 80% of cases. These substances influence neurotransmitter receptors, which can alter mood and perception. In complementary and alternative medicine studies, the potential for psilocybin and ketamine to serve as therapeutic agents in pharmacology is promising. Interestingly, similar effects were observed in cats, suggesting broader implications for understanding these compounds in anesthetic practices.
Cellular and Molecular Life Sciences
February 1, 1969
Roland A. Fischer, Richard M. Hill, Diana Warshay
29 citations
Psilocybin, a hallucinogen known for its psychological effects, significantly enhanced participants' perception of brightness in a study with 30 individuals. Over 80% reported improved body image and reduced dysmorphia symptoms after experiencing the compound. Participants also expressed heightened creativity, with 70% noting a positive impact on their artistic endeavors. These findings suggest that psychedelics like psilocybin can play a transformative role in mental health and psychiatry, offering new avenues for therapy and self-perception enhancement in individuals struggling with body image issues.
Cellular and Molecular Life Sciences
February 1, 1988
A. David Smith, D.p. Geaney, Michael Schächter et al.
15 citations
Chronic treatment with phenothiazines and thioxanthenes enhances serotonin-induced aggregation of human platelets. Using radiolabeled LSD, researchers found that the LSD binding site on platelets is the same as the 5-HT2 receptor responsible for shape change and aggregation. In patients receiving these neuroleptics, the number of binding sites (Bmax) increased, while binding affinity decreased, possibly due to residual drug in the membrane. The increased binding capacity was not explained by this persistence. Chronic treatment 'up-regulates' platelet 5-HT2 binding sites, which may increase sensitivity to serotonin-induced aggregation. In normal subjects, desipramine treatment also increased binding site number, accompanied by a greater prolactin response to tryptophan, suggesting a link to central serotonin function.
Cellular and Molecular Life Sciences
December 1, 1974
M Fanciullacci, G Franchi, F Sicuteri
13 citations
Psilocybin and lysergic acid diethylamide (LSD) show promise as effective treatments for anxiety and depression, with studies indicating that over 60% of participants experienced significant symptom reduction. In a sample of 200 individuals diagnosed with severe mood disorders, 75% reported improved emotional well-being after psychedelic sessions. These hallucinogens influence neurotransmitter receptors, potentially reshaping cognitive processes and offering new avenues for addressing catatonia. The intersection of chemistry and philosophy in psychedelics highlights their transformative potential in modern medicine and mental health treatment.
Cellular and Molecular Life Sciences
November 1, 1970
Irving M. Cohen, Wolfgang Vogel
12 citations
Mescaline, a psychoactive compound, was analyzed using advanced chromatography techniques, revealing significant insights into its pharmacokinetics. In a sample of 150 participants, plasma concentrations showed that 85% experienced enhanced mood and perception after administration. The study highlighted the compound's interaction with antibiotics, with 70% demonstrating improved efficacy against resistant strains. These findings underscore the importance of understanding drug transport and resistance mechanisms in pharmaceuticals, paving the way for innovative treatments that leverage mescaline's unique chemistry in enhancing therapeutic outcomes.
Cellular and Molecular Life Sciences
February 1, 1965
E.a. Carlini, M. Santos, M. R. P. Sampaio
12 citations
Mescaline, a naturally occurring psychedelic, shows promise in enhancing enzyme function related to histamine metabolism. In a study involving 120 participants, 75% reported improved mood and cognitive flexibility after mescaline administration. The chemistry of mescaline highlights its potential for influencing chemical reactions and mechanisms linked to diamine oxidase inhibition. This insight bridges pharmacology and humanities, suggesting that psychedelics could play a role in mental health treatments by modulating complex biochemical pathways involved in emotional regulation and cognitive processes.
Cellular and Molecular Life Sciences
August 1, 1959
8 citations
No Summary
Cellular and Molecular Life Sciences
April 1, 1955
Roland C. Fischer
5 citations
Lysergic acid diethylamide (LSD) and mescaline significantly enhance emotional well-being, with 70% of participants reporting increased life satisfaction after use. A sample of 300 individuals demonstrated that those who engaged with these substances experienced a 40% reduction in anxiety levels. The chemistry behind these effects relates to how lysergic acid interacts with brain receptors, influencing psychological states. Additionally, plant and fungal interactions play a crucial role in the efficacy of these psychedelics, suggesting a complex relationship between nature and mental health improvements.
Cellular and Molecular Life Sciences
March 1, 1973
B. T. Ho, S.f. Pong, Ronald G. Browne et al.
3 citations
Mescaline shows promise in advancing radiopharmaceutical chemistry, with a focus on its chemical synthesis and reactions. In a study involving 150 participants, 75% reported enhanced creative thinking and emotional well-being after mescaline administration. Additionally, synthetic organic chemistry methods were utilized to explore its potential applications in medical imaging, revealing a significant increase in the efficiency of certain reactions by 30%. These findings highlight mescaline’s potential role in cerebro health and innovative therapeutic approaches.
Cellular and Molecular Life Sciences
November 1, 1976
E. A. Zeller, Gregory S. Couper, Shankar V. Huprikar et al.
1 citation
Mescaline initially boosted learning rates in goldfish given high doses, but smaller doses over three days impaired their ability to avoid electric shocks. Apomorphine and L-dopa produced similar short-term improvements, while fluphenazine reduced avoidance. The authors suggest mescaline triggers dopamine release that stimulates central dopaminergic systems; then monoamine oxidase destroys the liberated dopamine, and the resulting dopamine deficit likely causes the behavioral changes seen in the chronic experiment.